C575881

3 trials

Sponsors

Takamura Masayuki, Osonoi Takeshi, Sakaguchi Kazuhiko

Conditions

Type 2 diabetes Type 2 diabetes, muscle sympathetic nerve activityType 2 diabetes mellitus Type 2 diabetes mellitustype 2 diabetes diabetes

Phase 2

A study investigating the effects of metformin and imeglimin on metal balance in patients with type 2 diabetes

RecruitingJPRN-jRCTs051260018

Sakaguchi Kazuhikotype 2 diabetes diabetes

Start: 2026-04-10Target: 64Updated: 2026-06-29

Unknown Phase

Effect of Imeglimin on muscle sympathetic nerve activiy in type 2 diabetes mellitus patients

RecruitingJPRN-jRCT1041220023

Takamura MasayukiType 2 diabetes Type 2 diabetes, muscle sympathetic nerve activity

Start: 2022-05-28Target: 30Updated: 2026-06-29

Comparative evaluation of clinical markers indicating hypoglycaemia treated with ImeglimiN and its eFfect on erythrocytes IN patIents with TYpe 2 diabetes

Active, not recruitingJPRN-jRCTs031220489

Osonoi TakeshiType 2 diabetes mellitus Type 2 diabetes mellitus

Start: 2022-12-05Target: 30Updated: 2026-06-29

Related Papers

Imeglimin may affect hemoglobin A1c accuracy via prolongation of erythrocyte lifespan in patients with type 2 diabetes mellitus: insights from the INFINITY clinical trial.

2025-10-24

Comparative evaluation of clinical glycemic control markers treated with imeglimin and its effect on erythrocytes in patients with type 2 diabetes mellitus: study protocol of a single-arm, open-label, prospective, exploratory trial

Frontiers in Pharmacology2023-06-072 citations